Evidence map›Paper›PMID 42338869›Full record

ArticleCureus2026

The Silent Infection: Cytokine Blockade, Blunted Sepsis Physiology, and Soft Tissue Infection With NLRP12-Associated Autoinflammatory Syndrome.

Alireza Izadian Bidgoli, Alberto Gomez Veliz

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alireza Izadian BidgoliInternal Medicine, American University of the Caribbean School of Medicine, Cupecoy, SXM.
Alberto Gomez VelizInternal Medicine, Jackson Memorial Hospital, Miami, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NLRP12-associated autoinflammatory syndrome is a rare monogenic autoinflammatory disease characterized by recurrent innate immune dysregulation and systemic inflammation. Distinguishing infection from hyperinflammatory disease activity in these patients is particularly challenging during cytokine-directed immunosuppressive therapy. We report a 20-year-old male with NLRP12/FCAS2-associated disease, systemic juvenile idiopathic arthritis (sJIA), and prior hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) who presented with bilateral gluteal cellulitis, recurrent fevers, and inflammatory biomarker elevation initially concerning for sepsis. Despite progressive soft tissue findings, the patient remained hemodynamically stable without leukocytosis, lactic acidosis, or positive blood cultures. Imaging demonstrated diffuse inflammatory thickening without organized abscess formation. Multidisciplinary evaluation suggested that the patient's recurrent fever pattern and sepsis-like physiology were driven predominantly by underlying cytokine dysregulation rather than uncontrolled systemic infection alone. Clinical improvement occurred following selective adjustment of immunosuppressive therapy in combination with antimicrobial treatment. This case highlights the emerging concept of "immune-modified infection," in which cytokine blockade alters the physiologic and biochemical manifestations of infection. In patients with autoinflammatory disease, inflammatory biomarker elevation may reflect immune amplification rather than microbial burden, complicating conventional sepsis assessment and management.

Indexed as

blunted sepsis physiologycytokine dysregulationinnate immune dysfunctionnlrp12-associated autoinflammatory diseasesoft tissue infection

Identifiers

PMID42338869
PMCPMC13285098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.